ArticleFrontiers in immunology2023

Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.

Yue Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.